Bradley Monk, MD, FACS, FACOG

Bradley Monk, MD, FACS, FACOG, discusses the rationale for investigating B7-H4–directed vedotin antibody-drug conjugates and highlights how these agents may address unmet needs for patients with gynecologic cancers.

Bradley Monk, MD, FACS, FACOG, discusses findings from the phase 2 RAMP 201 trial in patients with low-grade serous ovarian cancer and the importance of these results within the context of the larger ovarian cancer treatment paradigm.